Portola Stock Bleeds With Latest Drug Study Results
Insights - Portola used a unique study design in an attempt to enrich the trial and improve its odds of success. That might ultimately be betrixaban's undoing.
Read nowAuthor Archives: Jake King
Getting Non-Directional with Sarepta
Research - If you took our Sarepta Therapeutics (SRPT) trade from February, the diagonal has more than doubled in value. This is a great spot to cut … Continue Reading
Read now
GW Pharma Spotlights Epilepsy; Other Opportunities Abound
Research - The 100% move from GW Pharmaceuticals (GWPH) on Monday is a good opportunity to circle back on another mid-cap epilepsy player that’s down 40% year-to-date and 60% from its highs last year.
Premium
GW Pharma Rips Higher on New Epilepsy Data
Insights - Shares of GW Pharmaceuticals (GWPH) doubled on Monday with the much-anticipated release of positive data from a phase 3 study of Epidiolex, the company’s proprietary formulation of … Continue Reading
Read now
Quietly Plugging Away, Synergy in 2016
Research - It’s been some time since we’ve revisited Synergy Pharmaceuticals (SGYP). The company continues to guide for phase 3 plecanatide IBS-C data in the first half … Continue Reading
Premium
UniQure’s Finally a Sleeper: Timelines in Hemophilia
Research - UniQure (QURE) has essentially traded sideways since the company presented the first results from their ongoing open-label study of hemophilia gene therapy AMT-060 in January.
Read now
That Rally! For Now, Optimism is Back
Insights - Biotech had a Super Wednesday after Bernie Sanders’ not-so-super Tuesday.
Premium